CellWell record HH-462777
Feasibility of cystatin C as a biomarker for AECOPD severity: a cross-sectional study integrating CAT score, mMRC grade, and GOLD stage
Haoran Ma; Mengwen Yan; Jun Liu; Chen Zhu
2026
In plain language
In 389 hospitalized patients with COPD exacerbations, serum cystatin C rose with symptom and severity scores, and a 1.52 mg/L cutoff predicted severe symptom burden.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-462777
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.